Endoscopic Transsphenoidal Surgery for Acromegaly

Authors

  • SABA KHALID Department of Physiology and Cell Biology, University of Health Sciences, Lahore
  • KHALID MAHMOOD Department of Physiology and Cell Biology, University of Health Sciences, Lahore
  • TARIQ SALAHUDDIN Department of Physiology and Cell Biology, University of Health Sciences, Lahore

Keywords:

Growth hormone – secreting pituitary adenoma, Cavernous sinus, Remission induction

Abstract

Objective: The aim of this study was to determine the preoperative predictors of the extent of resection and endocrinological remission following endonasal endoscopic removal of growth hormone (GH) – secreting pituitary adenomas. Trans-sphenoidal surgery is the preferred treatment modality for growth hormone (GH) – secreting pituitary adenomas. In many series, the reported postoperative remission is based mainly on achieve-ment of GH levels less than 2 ng/ml. Strict criteria for insulin – like growth factor I normalization and even lower GH levels (< 1 ng/ml) are now suggested to define cure of acromegaly, but the evidence does not yet support such low GH levels in epidemiological follow-up. We analyzed our postoperative results in a sample of local popu-lation with acromegaly. Methods: Seven patients harboring GH – secreting adenomas (07 macroadenomas) underwent transsphenoidal surgery between 2005 and 2007 in Lahore General Hospital. The patient group included 03 women and 04 men of 23 – 50 years of age. All the patients were operated for the first time. Biochemical remission was defined as a repeated fasting or glucose – suppressed GH level of 2 ng/ml or less, and a normal insulin – like growth factor I level.
Results: The majority of acromegalic patients (83%) had macroadenomas > 1 cm in maximum diameter. Gross – total resection was achieved in 05 (71%) of 07 patients. Notably, endoscopic transsphenoidal surgery allowed complete resection of all lesions without cavernous sinus invasion, regardless of the suprasellar extent. Biochemical remission was achieved in 06 (85%) of 07 patients. A postoperative reduction in GH serum levels were associated with a higher rate of biochemical cure (p < 0.05). Significant differences were observed between pre- and postsurgical serum GH levels in male patients with Acromegalic tumors. Although mean serum GH concentrations were discernibly higher in patients as compared to controls (30.2 ± 3.1 vs 0.4 ± 0.1). In all the three premenopausal female patients included in the study, the individual presurgical serum GH levels were greater than those following surgery. The mean value was significantly higher than of the controls (38.9 ± 10.3 vs 0.2 ± 0.6 ng/ml, respectively).These values exceeded the normal serum GH concentrations described for healthy women (7 ng/ml or less). Following surgical removal of the adenoma, serum GH concentrations showed a marked decline of GH levels in all patients.
Conclusion: A purely endoscopic endonasal trans-sphenoidal adenoma resection leads to a high rate of gross – total tumor resection and endocrinological remission in acromegalic patients, even those harboring macro-adenomas with wide suprasellar extension. Extended approaches and angled endoscopes are useful tools for increasing the extent of resection. 

References

1. Abbassioun K, Amirjamshidi M, Mehrazin A, Khalat-bary I, Keynama M, Bokai H, et al : A prospective ana-lysis of 151 cases of patients with acromegaly operated by one neurosurgeon: a follow-up of more than 23 years. Surg Neurol 66: 26-31; discussion 31, 2006.
2. Beauregard C, Truong U, Hardy J, Serri O: Long – term outcome and mortality after transsphenoidal adenomec-tomy for acromegaly. Clin Endocrinol (Oxf) 2003; 58: 86-91.
3. Bolanowski M, Zatonska K, Kaluzny M, Zielinski G, Bednarek – Tupikowska G, Bohdanowicz – Pawlak A, et al : A follow-up of 130 patients with acromegaly in a single centre. Neuro Endocrinol Lett 2006; 27: 828-832.
4. Kim IM, Yim MB, Lee CY: The outcome of transsphe-noidal microsurgery for acromegaly. J Korean Neuro-surg Soc 2002; 32: 131-135.
5. Bush ZM, Vance ML: Management of acromegaly: is there a role for primary medical therapy? Rev Endocr Metab Disord 2008; 9: 83-94.
6. Carmichael JD, Bonert VS: Medical therapy: options and uses. Rev Endocr Metab Disord 2008; 9: 71-81.
7. Costa AC, Rossi A, Martinelli CE Jr, Machado HR, Moreira AC: Assessment of disease activity in treated acromegalic patients using a sensitive GH assay: should we achieve strict normal GH levels for a biochemical cure? J Clin Endocrinol Metab 2002; 87: 3142-3147.
8. De P, Rees DA, Davies N, John R, Neal J, Mills RG,Endoscopic Transsphenoidal Surgery for Acromegaly et al: Transsphenoidal surgery for acromegaly in wales : results based on stringent criteria of remission. J Clin Endocrinol Metab 2003; 88: 3567-3572.
9. Kreutzer J, Vance ML, Lopes MB, Laws ER Jr: Surgi-cal management of GH – secreting pituitary adenomas: an outcome study using modern remission criteria. J Clin Endocrinol Metab 2001; 86: 4072-4077.
10. Eastman RC, Gorden P, Glatstein E, Roth J: Radiation therapy of acromegaly. Endocrinol Metab Clin North Am 1992; 21: 693-712.
11. Fukuoka S, Ito T, Takanashi M, Hojo A, Nakamura H: Gamma knife radiosurgery for growth hormone – sec-reting pituitary adenomas invading the cavernous sinus. Stereotact Funct Neurosurg 2001; 76: 213-217.
12. Giustina A, Barkan A, Casanueva FF, Cavagnini F, Frohman L, Ho K, et al: Criteria for cure of acrome-galy: a consensus statement. J Clin Endocrinol Metab 2000; 85: 526-529.
13. Goffman TE, Dewan R, Arakaki R, Gorden P, Oldfield EH, Glatstein E: Persistent or recurrent acromegaly. Long-term endocrinologic efficacy and neurologic safe-ty of postsurgical radiation therapy. Cancer 1992; 69: 271-275.
14. Isono M, Inoue R, Kamida T, Kobayashi H, Matsuyama J: Significance of leptin expression in invasive potential of pituitary adenomas. Clin Neurol Neurosurg 2003; 105: 111-116.
15. Kawamoto H, Uozumi T, Kawamoto K, Arita K, Yano T, Hirohata T: Analysis of the growth rate and caver-nous sinus invasion of pituitary adenomas. Acta Neuro-chir (Wien) 1995; 136: 37-43.
16. Knosp E, Steiner E, Kitz K, Matula C: Pituitary ade-nomas with invasion of the cavernous sinus space: a magnetic resonance imaging classification compared with surgical findings. Neurosurgery 1993; 33: 610-617; discussion 617-618.
17. Landolt AM, Haller D, Lomax N, Scheib S, Schubiger O, Siegfried J, et al: Stereotactic radiosurgery for recur-rent surgically treated acromegaly: comparison with fractionated radiotherapy. J Neurosurg 1998; 88: 1002-1008.
18. Ludecke DK, Abe T: Transsphenoidal microsurgery for newly diagnosed acromegaly: a personal view after more than 1,000 operations. Neuroendocrinology 2006;83: 230-239.
19. Minniti G, Jaffrain – Rea ML, Esposito V, Santoro A, Tamburrano G, Cantore G: Evolving criteria for post-operative biochemical remission of acromegaly: can we achieve a definitive cure? An audit of surgical results on a large series and a review of the literature. Endocr Relat Cancer 2003; 10: 611-619.
20. Newman CB: Medical therapy for acromegaly. Endo-crinol Metab Clin North Am 1999; 28: 171-190.
21. Nomikos P, Buchfelder M, Fahlbusch R: The outcome of surgery in 668 patients with acromegaly using cur-rent criteria of biochemical ?cure‘. Eur J Endocrinol 2005; 152: 379-387.
22. Orme SM, McNally RJ, Cartwright RA, Belchetz PE: Mortality and cancer incidence in acromegaly: a retro-spective cohort study. United Kingdom Acromegaly Study Group. J Clin Endocrinol Metab 1998; 83: 2730-2734.
23. Petrovich Z, Yu C, Giannotta SL, Zee CS, Apuzzo ML: Gamma knife radiosurgery for pituitary adenoma: early results. Neurosurgery 2003; 53: 51-59; discussion 59-61.
24. Rajasoorya C, Holdaway IM, Wrightson P, Scott DJ, Ibbertson HK: Determinants of clinical outcome and survival in acromegaly. Clin Endocrinol (Oxf) 1994; 41: 95-102.
25. Shimon I, Cohen ZR, Ram Z, Hadani M: Transsphe-noidal surgery for acromegaly: endocrinological fol-low-up of 98 patients. Neurosurgery 2001; 48: 1239-1243; discussion 1244-1245.
26. Swearingen B, Barker FG 2nd, Katznelson L, Biller BM, Grinspoon S, Klibanski A, et al: Long – term mor-tality after transsphenoidal surgery and adjunctive the-rapy for acromegaly. J Clin Endocrinol Metab 1998; 83: 3419-3426.
27. Trouillas J, Daniel L, Guigard MP, Tong S, Gouvernet J, Jouanneau E, et al: Polysialylated neural cell adhe-sion molecules expressed in human pituitary tumors and related to extrasellar invasion. J Neurosurg 2003; 98: 1084-1093.
28. Zhang N, Pan L, Wang EM, Dai JZ, Wang BJ, Cai PW: Radiosurgery for growth hormone – producing pituitary adenomas. J Neurosurg 2000; 93 (Suppl 3): 6-9.

Downloads

Published

2018-11-04

Issue

Section

Original Articles